ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Remains Exception To NIH Authority Over Scientific Counselors

January 27, 1995

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

December 30, 2011

Cancer Control Budget Still $4 Million Short

January 28, 1977

In Brief: William Paul to Head AIDS Research Officer; Schachman Is NIH Extramural Obudsman

February 25, 1994

DCPC Advisers Ok Four New Grant Programs To Foster Prevention

May 22, 1992

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

November 29, 2002